ArticleApplied microbiology and biotechnology2026
Antifungal efficacy of a novel type of nanosalt against human fungal pathogens and its antifungal mechanisms.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of invasive fungal infections is rising steadily, driven by the expanding immunocompromised patient population and the limited availability of effective antifungal interventions. Among medically important fungi, airborne Aspergillus conidia are especially relevant to environmental quality control because they can disseminate through air and contaminate healthcare settings. Here, we designed and synthesized a novel ultrafine sodium chloride powder (nanosalt) by anti-solvent precipitation coupled with high-energy nanonization and evaluated its in vitro antifungal activity in a controlled spray co-exposure system using Aspergillus spp. as the primary airborne fungal species. In addition, Candida albicans and Cryptococcus neoformans were also to be tested for the antifungal broad-spectrum by this system even though they do not belong to typical hospital airborne transmission. Nanosalt showed marked fungicidal activity against the tested human fungal pathogens. Further morphological observations in nanosalt-treated A. fumigatus conidia indicated severe cell wall and membrane damage, pore-like structural disruption, leakage-associated loss of integrity accompanied with a time-dependent increase of fungal intracellular reactive oxygen species. Findings in this study mainly identify nanosalt not only might be efficient anti-airborne fungal pathogens but also could be a potential broad-spectrum antifungal reagents. Although currently used aerosol chamber model still has limitation compared actual clinical environment, future practical air-disinfection applications in clinics and related biosafety evaluations are still required. KEY POINTS: • Novel nanosalt particles were generated by anti-solvent precipitation coupled with high-energy nanonization. • Nanosalts exhibit broad fungicidal activity by disrupting fungal cell walls and membranes. • Nanosalt is a candidate for dry environmental antifungal disinfectant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.